Table 1.
Demographic and clinical characteristics of 150 haemodialysis patients (mean and 95% CI)
| All (n = 150) | Men (n = 92) | Women (n = 58) | Statistical significance men vs. women | |
|---|---|---|---|---|
| Age (years) | 62 (59–64) | 62 (59–65) | 61 (57–65) | NS |
| Body mass index (kg/m2) | 26.1 (25.3–27.0) | 26.6 (25.7–27.5) | 25.4 (23.7–27.0) | NS |
| BMI ≥ 30 kg/m2 (n/%) | 29/19.3 | 18/19.6 | 11/19.0 | |
| Time on dialysis (months) | 49 (41–56) | 50 (39–61) | 46 (36–56) | NS |
| Kt/V (per HD session)a | 1.05 (1.01–1.08) | 0.98 (0.94–1.02) | 1.15 (1.09–1.20) | p < 0.001 |
| Ultrafiltration (L) | 2.5 (2.3–2.6) | 2.5 (2.3–2.7) | 2.5 (2.2–2.7) | NS |
| Primary cause of CKD (n/%) | ||||
| Diabetes | 42/28.0 | 27/29.3 | 15/25.8 | |
| Hypertension | 17/11.3 | 13/14.1 | 4/6.9 | |
| Nephrolithiasis | 8/5.3 | 4/4.3 | 4/6.9 | |
| ADPKD | 10/6.7 | 4/4.3 | 6/10.3 | |
| Ischemic nephropathy | 2/1.3 | 1/1.0 | 1/1.9 | |
| Glomerulonephritis | 24/16.0 | 15/16.3 | 9/15.5 | |
| Interstitial nephritis | 13/8.5 | 3/3.2 | 10/17.2 | |
| Other or unknown | 34/22.7 | 25/27.5 | 9/15.5 | |
| Co-morbidities (%) | ||||
| Hypertension | 136/90.7 | 86/93.5 | 50/86.2 | |
| Diabetes | 55/36.7 | 36/39.1 | 19/32.6 | |
| Coronary artery disease | 83/55.3 | 57/62.0 | 26/44.8 | |
| Stroke | 12/8.0 | 9/9.8 | 3/5.2 | |
| Past kidney transplantation | 11/7.3 | 8/8.7 | 3/5.2 | |
| CKD-MBD Pharmacotherapy (n/%) | ||||
| Oral phosphorous binders | 143/94.7 | 89/96.7 | 54/93.1 | |
| Carbonate calcium dose (g/day) | 3.0 (2.6–3.5) | 2.9 (2.4–3.5) | 3.1 (2.4–3.8) | NS |
| Sevelamer hydrochloride | 4/2.6 | 2/2.1 | 2/3.4 | |
| Cinacalcet | 17/11.3 | 8/8.7 | 9/15.5 | |
| Cinacalcet dose (mg/day) | 10.1 (5.1–15.1) | 6.7 (1.6–11.9) | 15.6 (5.3–25.8) | NS |
| Alfacalcidol | 40/26.7 | 23/25.0 | 17/29.3 | |
| Haemoglobin (g/dL)a | 10.8 (10.6–11.0) | 10.8 (10.6–11.1) | 10.7 (10.4–11.0) | NS |
| Total cholesterol (mg/dL) | 169 (160–177) | 159 (148–170) | 184 (171–198) | p < 0.01 |
| LDL cholesterol (mg/dL) | 90 (84–95) | 84 (77–91) | 98 (89–107) | 0.01 |
| HDL cholesterol (mg/dL) | 28 (26–29) | 27 (25–29) | 28 (26–30) | NS |
| Triglycerides (mg/dl) | 159 (142–177) | 151 (127–175) | 171 (147–196) | NS |
| Phosphorus (mmol/L)a | 5.77 (5.52–6.02) | 5.7 (5.4-6.0) | 5.84 (5.4–6.3) | NS |
| Calcium (mg/dL)a | 8.57 (8.44–8.70) | 8.6 (8.4–8.7) | 8.6 (8.3–8.8) | NS |
| Parathyroid hormone (pg/mL)a | 446 (329–563) | 376 (308–445) | 565 (424–706) | p < 0.01 |
| cFGF23 (RU/mL)b | 1582 (1381–1782) | 1615 (1352–1878) | 1527 (1209–1846) | NS |
| 25-OH-D (ng/mL) | 12.8 (11.0–14.6) | 14.8 (12.5–17.0) | 9.6 (6.8–12.4) | p < 0.01 |
| Osteocalcin (ng/mL)b | 147 (133–160) | 140 (124–156) | 158 (133–182) | NS |
| total P1NP (ng/mL)b | 312 (261–364) | 271 (215–327) | 379 (280–477) | p < 0.05 |
| β-CTx (ng/mL) * | 1.65 (1.47–1.83) | 1.61 (1.38–1.86) | 1.69 (1.42–1.97) | NS |
| ALP (U/L) ^ | 115 (98–132) | 109 (91–126) | 124 (91–158) | NS |
| hs-CRP (mg/L)b | 9.0 (7.3–10.8) | 9.1 (7.0-11.2) | 8.8 (5.8–11.9) | NS |
| IL-6 (pg/mL)b | 6.7 (5.6–7.8) | 7.5 (6.0–9.0) | 5.37 (3.82–6.92) | p = 0.06 |
| TNF-α (pg/mL)b | 9.6 (7.6–11.6) | 9.8 (7.6–12.1) | 9.3 (5.3–13.2) | NS |
| Sclerostin (ng/mL)b | 1.88 (1.23–3.01) | 2.15 (1.44–3.25) | 1.55 (0.99–2.47) | p < 0.01 |
BMI Body Mass Index, ADPKD Autosomal Dominant Polycystic Kidney Disease, LDL Low-Density Lipoprotein, HDL High-Density Lipoprotein, cFGF23 C-terminal Fibroblast Growth Factor 23 Calcitriol, 1,25(OH)2D3 1,25-dihydroksycholekalcyferol, P1NP Procollagen I Aminoterminal propeptide, β-CTx C-terminal telopeptide, ALP Alkaline phosphatase, hs-CRP High-sensitivity C-reactive protein, TNF-α Tumour Necrosis Factor - α, IL-6 Interleukin- 6
aMean value from last 6 month
bMedian (1Q-3Q)